Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,361,850.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00. Following the completion of the transaction, the chief executive officer owned 643,209 shares in the company, valued at $62,346,248.37. This trade represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Up 2.2%

BNTX traded up $2.13 during trading on Monday, hitting $98.86. The company’s stock had a trading volume of 1,212,282 shares, compared to its average volume of 1,111,191. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $96.98 and its 200-day moving average price is $95.27. The firm has a market capitalization of $25.00 billion, a P/E ratio of -12.63 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period last year, the business earned ($1.60) EPS. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Analyst Ratings Changes

BNTX has been the subject of several research reports. Canaccord Genuity Group reduced their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Citigroup cut their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Finally, Morgan Stanley decreased their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BNTX. Flossbach Von Storch SE bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $207,142,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. First Trust Advisors LP grew its holdings in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after purchasing an additional 451,124 shares during the period. Assenagon Asset Management S.A. bought a new position in BioNTech during the second quarter valued at $39,385,000. Finally, SEB Asset Management AB purchased a new stake in BioNTech in the first quarter worth $17,804,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.